Henlius Unveils Ambitious 'Globalization 2.0' Strategy and Innovation Roadmap at JPM 2026

Henlius Announces 'Globalization 2.0' Strategy at JPM 2026

The 44th J.P. Morgan Healthcare Conference (JPMHC) ran from January 12-15, 2026, in San Francisco, showcasing significant developments in the healthcare sector. Among the standout presentations was that of Dr. Jason Zhu, Executive Director and CEO of Shanghai Henlius Biotech, Inc. (2696.HK), who outlined the company's ambitious 'Globalization 2.0' strategy and medium- to long-term innovation plans.

Expanding Global Reach

Henlius is poised to escalate its international operations, with projections indicating the launch of over 20 products by 2030, especially targeting U.S. and European markets. Dr. Zhu emphasized the organization's commitment to continuous innovation and its growing global presence, leveraging its integrated research and development capabilities, regulatory expertise, and manufacturing competencies.

"With numerous product approvals in Europe and the U.S., our integrated global operational model is rapidly maturing, allowing us to maintain robust growth," said Dr. Zhu. He added that Henlius aims to reinforce its capacity to deliver innovative assets consistently worldwide.

Innovative Product Pipeline

The company's strategy includes stable cash flows from its biosimilar portfolio, which will further bolster investments into innovation. This will facilitate advancements in differentiated molecules such as Antibody Drug Conjugates (ADCs), multi-specific antibodies (multi-Abs), and T Cell Engagers (TCEs) in international markets. Henlius provided insights into its key innovations set for development in 2026, including:

- Serplulimab (Hetronifly®): An anti-PD-1 monoclonal antibody,
- HLX22: A new epitope anti-HER2 monoclonal antibody,
- HLX43: A PD-L1 ADC,
- HLX07: An anti-EGFR monoclonal antibody.

Diversified Preclinical Portfolio

Henlius's preclinical asset portfolio spans numerous molecular modalities, prioritizing solid tumors. The strategy is specifically designed to target established and emerging targets such as PD-(L)1, DLL3, B7-H3, HER2, EGFR, c-Met, and KAT6A/B.

The portfolio will comprise an equitable mix of First-in-Class (FIC) and Best-in-Class (BIC) candidates, alongside fast-tracked programs with higher clinical and commercialization certainty, laying a sturdy framework for sustainable clinical pipeline advancement.

By proactively structuring its preclinical portfolio to encompass various innovation profiles—including FICs, BICs, and rapid-follow programs—Henlius is building a multi-level R&D architecture that harmonizes cutting-edge innovation with efficient development and risk management.

Conclusion

As Henlius embarks on its 'Globalization 2.0' journey, its comprehensive plans highlight a commitment to innovation and growth within the healthcare landscape, promising to deliver impactful therapies to patients globally. With concrete steps outlined for the upcoming years, the company demonstrates its dedication to becoming a leader in the biopharmaceutical industry while fostering improvements in patient care through groundbreaking innovations.